1. Home
  2. TNXP vs HYZN Comparison

TNXP vs HYZN Comparison

Compare TNXP & HYZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNXP
  • HYZN
  • Stock Information
  • Founded
  • TNXP 2007
  • HYZN 2020
  • Country
  • TNXP United States
  • HYZN United States
  • Employees
  • TNXP N/A
  • HYZN N/A
  • Industry
  • TNXP Biotechnology: Pharmaceutical Preparations
  • HYZN Construction/Ag Equipment/Trucks
  • Sector
  • TNXP Health Care
  • HYZN Consumer Discretionary
  • Exchange
  • TNXP Nasdaq
  • HYZN Nasdaq
  • Market Cap
  • TNXP 19.5M
  • HYZN 14.3M
  • IPO Year
  • TNXP N/A
  • HYZN N/A
  • Fundamental
  • Price
  • TNXP $0.61
  • HYZN $1.14
  • Analyst Decision
  • TNXP Strong Buy
  • HYZN Strong Buy
  • Analyst Count
  • TNXP 2
  • HYZN 1
  • Target Price
  • TNXP $53.50
  • HYZN $80.00
  • AVG Volume (30 Days)
  • TNXP 202.6M
  • HYZN 215.7K
  • Earning Date
  • TNXP 11-12-2024
  • HYZN 11-13-2024
  • Dividend Yield
  • TNXP N/A
  • HYZN N/A
  • EPS Growth
  • TNXP N/A
  • HYZN N/A
  • EPS
  • TNXP N/A
  • HYZN N/A
  • Revenue
  • TNXP $11,291,000.00
  • HYZN $10,725,000.00
  • Revenue This Year
  • TNXP $62.53
  • HYZN $3,703.39
  • Revenue Next Year
  • TNXP $26.17
  • HYZN N/A
  • P/E Ratio
  • TNXP N/A
  • HYZN N/A
  • Revenue Growth
  • TNXP 183.05
  • HYZN 1262.77
  • 52 Week Low
  • TNXP $0.12
  • HYZN $0.95
  • 52 Week High
  • TNXP $14.08
  • HYZN $46.00
  • Technical
  • Relative Strength Index (RSI)
  • TNXP 75.02
  • HYZN 26.11
  • Support Level
  • TNXP $0.32
  • HYZN $1.81
  • Resistance Level
  • TNXP $0.72
  • HYZN $1.96
  • Average True Range (ATR)
  • TNXP 0.15
  • HYZN 0.14
  • MACD
  • TNXP 0.04
  • HYZN -0.04
  • Stochastic Oscillator
  • TNXP 39.61
  • HYZN 16.35

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

About HYZN Hyzon Motors Inc.

Hyzon Motors Inc assembles and supplies hydrogen fuel cell-powered commercial vehicles across North America, Europe, China, and Australasia. In addition, it builds and fosters a clean hydrogen supply ecosystem with partners from feedstocks through production, dispensing and financing. The company intends to meet its customers' zero-emission vehicle needs by electrifying proven vehicle platforms utilizing its industry- leading fuel cell and electric propulsion technologies. It expects to deploy these technologies in various vehicle classes, including heavy-duty and medium-duty trucks and buses with the potential for future expansion into light-duty commercial vehicles, additional mobility use cases and stationary power applications.

Share on Social Networks: